{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:48:42Z","timestamp":1793645322362,"version":"4.5.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.06.062","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T07:38:24Z","timestamp":1595230704000},"page":"5793-5802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates"],"prefix":"10.1016","volume":"38","author":[{"given":"Morgan A.","family":"Monslow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayda","family":"Elbashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Thiriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thoryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Citron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Thambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Hazuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpit A.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"RR-5","key":"10.1016\/j.vaccine.2020.06.062_b0005","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2020.06.062_b0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cger.2016.02.011","article-title":"Herpes zoster","volume":"32","author":"Schmader","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"10","key":"10.1016\/j.vaccine.2020.06.062_b0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.vaccine.2020.06.062_b0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/tid.12180","article-title":"Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity","volume":"16","author":"Vermont","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.06.062_b0025","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.062_b0030","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2020.06.062_b0035","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2020.06.062_b0040","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.06.062_b0045","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.06.062_b0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.06.062_b0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2020.06.062_b0060","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2020.06.062_b0065","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2020.06.062_b0070","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.06.062_b0075","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.06.062_b0080","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/infdis\/jix482","article-title":"Immunogenicity and safety of the HZ\/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine","volume":"216","author":"Grupping","year":"2017","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2020.06.062_b0085","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/21645515.2016.1265715","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults >\/= 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial","volume":"13","author":"Godeaux","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2020.06.062_b0090","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2020.06.062_b0095","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.06.062_b0100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1134\/S0006297916070075","article-title":"mRNA-based therapeutics \u2013 advances and perspectives","volume":"81","author":"Sergeeva","year":"2016","journal-title":"Biochemistry (Mosc)"},{"issue":"3","key":"10.1016\/j.vaccine.2020.06.062_b0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0166-0934(90)90100-T","article-title":"Enhancement of varicella-zoster virus plaquing efficiency with an agarose overlay medium","volume":"27","author":"Krah","year":"1990","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2020.06.062_b0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"169","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.vaccine.2020.06.062_b0115","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"issue":"22","key":"10.1016\/j.vaccine.2020.06.062_b0120","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1128\/JVI.78.22.12406-12415.2004","article-title":"Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo","volume":"78","author":"Moffat","year":"2004","journal-title":"J Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2020.06.062_b0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00269-18","article-title":"Breadth and functionality of varicella-zoster virus glycoprotein-specific antibodies identified after zostavax vaccination in humans","volume":"92","author":"Sullivan","year":"2018","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.06.062_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"issue":"6","key":"10.1016\/j.vaccine.2020.06.062_b0135","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.vaccine.2020.06.062_b0140","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.vaccine.2020.06.062_b0145","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","article-title":"Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells","volume":"182","author":"Lindenstrom","year":"2009","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2020.06.062_b0150","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.06.062_b0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","article-title":"Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques","volume":"15","author":"Pardi","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"25","key":"10.1016\/j.vaccine.2020.06.062_b0160","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.06.062_b0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.molmed.2013.09.002","article-title":"Challenges and advances towards the rational design of mRNA vaccines","volume":"19","author":"Pollard","year":"2013","journal-title":"Trends Mol Med"},{"issue":"7","key":"10.1016\/j.vaccine.2020.06.062_b0170","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","article-title":"Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus","volume":"212","author":"Laing","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.062_b0175","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fimmu.2015.00553","article-title":"Effector and central memory poly-functional CD4(+) and CD8(+) T cells are boosted upon ZOSTAVAX((R)) vaccination","volume":"6","author":"Sei","year":"2015","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.06.062_b0180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmv.1890140403","article-title":"Immunogenicity of wild and attenuated varicella-zoster virus strains in rhesus monkeys","volume":"14","author":"Asano","year":"1984","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2020.06.062_b0185","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1128\/JVI.03124-14","article-title":"Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge","volume":"89","author":"Meyer","year":"2015","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2020.06.062_b0190","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1586\/erv.11.93","article-title":"Molecular studies of the Oka varicella vaccine","volume":"10","author":"Quinlivan","year":"2011","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:46:22Z","timestamp":1759401982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20308483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":38,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X20308483"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}